New Open MRI System from Fujifilm Combines Technology Advances with Patient Comfort
The Aperto Lucent open 0.4T MRI platform reportedly offers enhanced fat suppression and spatial resolution capabilities in addition to its open architecture design.
Emphasizing patient comfort, workflow efficiencies and enhanced imaging quality, Fujifilm has launched the Aperto Lucent open 0.4T magnetic resonance imaging (MRI) system.
The system’s wide laterally moving table and single-pillar design are key factors in promoting patient comfort, according to Fujifilm.
In addition to the platform’s permanent magnet technology, the company said the Aperto Lucent provides an array of features to facilitate efficient quality imaging.
In addition to promoting patient comfort, the Aperto Lucent open 0.4T MRI system reportedly provides enhanced fat suppression capabilities and improved spatial resolution. (Image courtesy of Fujifilm.)
• Fat suppression features include eight channels of active patient shimming and chemical shift-selective (CHESS) type radiofrequency (RF) fat saturation, which complements short tau inversion recovery (STIR) sequences.
• A combination of solenoid technology RF receiver coils and the IP-Recon iterative image reconstruction algorithm facilitate a high signal-to-noise ratio (SNR) and enhanced spatial resolution, according to Fujifilm.
• In order to address challenges with patient motion, Fujifilm said the Aperto Lucent system has RADAR motion compensating pulse sequence technology that reduces artifacts and the potential for rescans.
“APERTO Lucent is a perfect solution for providers looking for a space-saving, cost-effective system that enhances the MRI patient experience,” noted Shawn Etheridge, the executive director of modality solutions marketing for Fujifilm Healthcare Americas Corporation. “With permanent magnet open MRI technology, there is little need for additional equipment and infrastructure to maintain the magnetic field, keeping installation and operating costs low for our customers and providing a stronger return on investment.”
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
